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Summary
Although the class IA phosphoinositide 3-kinase (PI3K) pathway is central to the metabolic actions of insulin, its mechanism
of action is not well understood. To identify the role of the PI3K pathway in insulin regulation of hepatic function, we ablated
the expression of both major regulatory subunits of PI3K by crossing mice lacking Pik3r1 in liver with Pik3r2 null mice, cre-
ating liver-specific double knockout mice (L-p85DKO). L-p85DKO mice failed to activate PI3K or generate PIP3 upon insulin
stimulation or activate its two major effectors, Akt and PKCl/x. Decreased Akt activation resulted in increased gluconeo-
genic gene expression, impaired glucose tolerance, and hyperinsulinemia, while the defective activation of PKCl/x by insulin
was associated with hypolipidemia and decreased transcription of SREBP-1c. These data indicate that the PI3K pathway is
critical for insulin’s actions in the liver in vivo, and that differential regulation by Akt and PKCl/x differentially defines specific
actions of insulin and PI3K on hepatic glucose and lipid metabolism.Introduction
Class IA phosphoinositide 3-kinase (PI3K) is a critical mediator of
insulin action in the liver (Taniguchi et al., 2006). Following insulin
stimulation of its receptor, PI3K generates the second messen-
ger phosphatidylinositol(3,4,5)-trisphosphate (PIP3), which then
activates several downstream targets such as Akt and atypical
forms of protein kinase C (PKC l/z) via their colocalization with
PDK1. The PI3K-dependent activation of Akt defines many as-
pects of the insulin-mediated regulation of hepatic glucose
metabolism. Akt suppresses gluconeogenesis and activates
glycogen synthesis via its phosphorylation of FoxO1 (Zhang
et al., 2002) and GSK3b (Cross et al., 1995), respectively. The
PI3K/Akt axis also regulates cell growth via the phosphorylation
and inhibition of hamartin and tuberin (TSC1 and TSC2) (Potter
et al., 2002), which effectively activates the mTOR pathway
resulting in phosphorylation of p70S6kinase and 4EBP1and
stimulation of protein synthesis and cell growth (Harris and
Lawrence, 2003).
Insulin also promotes hepatic lipogenesis through several
mechanisms, the most prominent of which is upregulation of
sterol regulatory element binding protein-1c (SREBP-1c), a tran-
scription factor that potently activates the lipogenic program
(Shimomura et al., 1999). The components of the PI3K pathway
that are responsible for this increase in SREBP-1c expression
are not well understood. Indeed, while Akt has potent effects
on glucose metabolism, it exhibits only modest effects on lipo-
genesis and SREBP-1c mRNA levels both in vitro (FleischmannCELL METABOLISM 3, 343–353, MAY 2006 ª2006 ELSEVIER INC. DOand Iynedjian, 2000) and in vivo (Ono et al., 2003). Moreover,
much of Akt’s lipogenic effect may occur independently of
SREBP (Ono et al., 2003). Recently, the atypical PKC isoforms
l and z that are activated by PI3K have been shown to be re-
quired for insulin-dependent increases in the expression of
SREBP-1c (Farese et al., 2005). Thus, a liver-specific knockout
of PKCl leads to a marked decrease in SREBP-1c expression,
with little effect on the expression of gluconeogenic genes,
such as phosphoenolpyruvate carboxykinase (PEPCK) and glu-
cose 6-phosphatase (G6Pase), suggesting that the atypical
PKCs may positively regulate SREBP-1c expression in vivo
(Matsumoto et al., 2003).
The dissection of the multiple functions of PI3K in vivo by ge-
netic deletion has been difficult to achieve. Mammalian PI3K is
aheterodimer that consists of anSH2-containing regulatory sub-
unit (p85) and a catalytic subunit (p110), with both subunits ex-
pressed inmultiple isoforms. There are eight isoforms of the reg-
ulatory subunit encoded by three different genes, Pik3r1, Pik3r2,
and Pik3r3. In most cells, the gene products of Pik3r1 constitute
65%–75% of the intracellular pool of regulatory subunits in the
form of p85a and its two shorter isoforms p55a and p50a (Ueki
et al., 2000), while Pik3r2 accounts for 20%–30% of the regula-
tory subunits in the form of p85b (Ueki et al., 2003). The catalytic
subunit of class IA PI3K is also represented by three different
isoforms—p110a, p110b, and p110d—each of which is pro-
duced from a distinct gene (reviewed in Shepherd et al., 1998).
The complex roles of the PI3K subunits in embryonic develop-
ment andmetabolic homeostasis haveconfoundedconventionalI 10.1016/j.cmet.2006.04.005 343
A R T I C L Eknockout studies of both the regulatory and catalytic subunits of
PI3K. For instance, global knockouts of the p110a or p110b
catalytic subunits cause early embryonic lethality (Bi et al.,
2002; Bi et al., 1999), and the whole-body knockout of Pik3r1 re-
sults in perinatal lethality (Fruman et al., 2000).
To study the effect of the in vivo loss of the PI3K pathway on
hepatic glucose and lipid homeostasis and to circumvent the
lethality encountered in various global knockouts of PI3K sub-
units, we have created mice which lack all PI3K regulatory sub-
units in liver (L-p85DKO) by crossing mice in which the Pik3r1
gene (producing p85a, p55a, and p50a) is specifically inacti-
vated in the liver (L-aKOmice) with Pik3r2 knockout mice, which
lack the other major p85 isoform, p85b, in all tissues. We find
that deletion of both Pik3r1 and Pik3r2 in the liver completely ab-
lates PI3K activity and the accumulation of PIP3 resulting in
a 90% decrease in Akt and PKCl/z activation. By reconstitution
experiments, we show that the loss of Akt activity in the
L-p85DKO animals is linked to the defects in glucose homeosta-
sis such as glucose intolerance and increased expression of
gluconeogenic genes, while decreased PKCl/z activity is asso-
ciated with lower mRNA levels of SREBP-1c and hypolipidemia.
These data suggest that the insulin/PI3K pathway regulates
hepatic glucose and lipid homeostasis via distinct mediators,
with Akt playing a more important role in the former and
PKCl/z activating the latter.
Results
L-p85DKO mice have significant defects
in insulin-stimulated PIP3 generation
Mice lacking Pik3r1 and Pik3r2 in liver were generated by cross-
ing mice that were both homozygous for a floxed allele of Pik3r1
(Luo et al., 2005) and heterozygous for the albumin-Cre trans-
gene (Postic and Magnuson, 2000) with mice homozygous for
both the Pik3r1 floxed allele and the Pik3r2 null allele (Ueki
et al., 2002). Thus, these matings produced mice deleted of
Pik3r1 specifically in liver on a global p85b knockout back-
ground, i.e., a double knockout of Pik3r1 and Pik3r2 in liver
(L-p85DKO). This breeding strategy (see Experimental Proce-
dures) also generated four other study groups: Pik3r1 homozy-
gous floxed controls (FLOX), Pik3r1 homozygous floxed mice
that also lack Pik3r2 (bKO), as well as mice with Pik3r1 ablated
only in liver either on a wild-type (wt) background (L-aKO) or
on aPik3r2 heterozygous background (L-aKObH).Western blot-
ting with a pan-p85 antibody directed against the common C
terminus of the regulatory subunits revealed anw90%decrease
of hepatic p85a and p50a expression in mice with a deletion of
Pik3r1 in liver, which is consistent with the amount of protein
derived from hepatocytes (Figure 1A and Fruman et al., 2000).
Since the pan-p85a antibody only weakly detects p85b and
there are no good existing antibodies for p85bWestern blotting,
we confirmed the deletion of p85b by quantitative RT-PCR. In-
deed, mice that were homozygous for a Pik3r2 null allele ex-
hibited no detectable levels of p85b mRNA after 40 cycles of
quantitative RT-PCR, while mice heterozygous for Pik3r2 dis-
played a 30% decrease of p85b mRNA (Figure 1B).
The genetic ablation of the regulatory subunits also de-
creased total hepatic PI3K activity to levels commensurate
with p85 expression. Thus, when total PI3K activity was mea-
sured from phosphotyrosine (pTyr) immunoprecipitates of liver
lysates, bKO animals that lack only 20% of total regulatory sub-344units exhibited no differences from FLOX controls. More severe
disruptions of p85 expression, as in the L-aKO (L-Pik3r12/2,
Pik3r2+/+) or the L-aKObH (L-Pik3r12/2, Pik3r2+/2) mice, caused
a 50% and 70% reduction in pTyr-associated PI3K activity, re-
spectively (Figure 1C). As expected, when all four alleles of the
regulatory subunits were deleted (L-Pik3r12/2, Pik3r22/2;
L-p85DKO), insulin failed to stimulate PI3K activity above basal
levels. In general, IRS-1- and IRS-2-associated PI3K activity re-
flected total PI3K activity, except that the loss of one or both al-
leles of Pik3r2 resulted in increased IRS-2 activity, as previously
noted (Ueki et al., 2002).
Germline knockouts of the regulatory subunit of PI3K have
been complicated by discrepancies between PI3K activity and
PIP3 levels due to various compensatory effects (Terauchi
et al., 1999). To determine levels of the second messenger
PIP3 in these knockout animals, we utilized an in situ immunoflu-
orescence technique that allowed us to semiquantitatively mea-
sure PIP3 levels in hepatocytes with an anti-PIP3 antibody
(Figure 1D; Kitamura et al., 2004). Surprisingly, PIP3 levels in
bKO and L-aKOmice were not statistically different from control
FLOX mice, despite a 50% decrease in total PI3K activity in the
latter (Figure 1C).More stringent deletions of regulatory subunits
did produce statistically significant decreases in PIP3 levels.
L-aKObH mice showed a 50% impairment of PIP3 generation,
while insulin-stimulated PIP3 production in L-p85DKO mice
was barely above basal levels. Thus, genetic ablation of the ma-
jor regulatory subunit isoforms encoded by Pik3r1 and Pik3r2
can disrupt PI3K activity and function but only after severe de-
letions of at least three of the four major alleles encoding regu-
latory subunits.
Akt signaling is significantly impaired in L-p85DKO mice
The generation of PIP3 by PI3K ultimately activates Akt, atypical
PKCs, and other PH domain-containing proteins. As expected,
L-p85DKO mice showed a 90% decrease in Akt activation, as
measured by phosphorylation of serine 473 in Akt (Figure 2A).
This correlated with impaired phosphorylation/activation of
downstream Akt targets, including FoxO1 and GSK3b (Fig-
ure 2A). The phosphorylation of TSC2 was also significantly im-
paired (Figure 2B). Since TSC2 controls cell growth and protein
synthesis via the mTOR/p70S6K pathway, we determined
whether the loss of PI3K activity also disrupted mTOR signaling
bymeasuring S6 phosphorylation since phosphorylation of ribo-
somal S6 is one of the ultimate downstream results of mTOR ac-
tivation. As expected, insulin stimulation of S6 ribosomal protein
phosphorylation exhibited a marked decrease in liver of
L-aKObH mice and was absent in L-p85DKO mice (Figure 2B).
Recent evidence has demonstrated that the different Akt iso-
forms may have unique roles in metabolic homeostasis (Jiang
et al., 2003), with Akt2 playing a particularly dominant role in he-
patic metabolism (Cho et al., 2001). To determine if the Akt
isoforms were differentially affected by the deletion of p85, we
measured the kinase activity of Akt1 (Figure 2C) and Akt2
(Figure 2D) using isoform-specific antibodies (Sakamoto et al.,
2002). The kinase activities of both Akt1 and Akt2 paralleled
Ser473 phosphorylation of Akt, with activity remaining normal
unless all four alleles of p85 were deleted (Figures 2C and 2D).
These data suggest that Akt is exquisitely sensitive to PIP3
levels, and that even with a 50% decrease in PIP3 generation,
there is sufficient PIP3 to promote the full activation of all Akt
isoforms.CELL METABOLISM : MAY 2006
PI3K-mediated regulation of hepatic metabolismFigure 1. L-p85DKO mice have defective insulin-stimulated PI3K activity in liver
A) Immunoblot with a pan-p85a from liver lysates of mice of the indicated genotypes.
B) Quantitative RT-PCR analysis of p85b message levels. Bars represent means 6 SEM, n = 6–8, *p < 0.05 compared to FLOX.
C) PI3K activity in pTyr, IRS-1, and IRS-2 immunoprecipitates. Bars represent means 6 SEM, n = 4, *p < 0.05 compared to insulin stimulated FLOX.
D) (Top) Immunofluorescent staining with a primary anti-PIP3 antibody (IgM) and an anti-mouse secondary antibody conjugated to Alexafluor Red. The sections were coun-
terstained with DAPI. (Bottom) Quantification of the immunofluorescence from PIP3 staining. Four representative slides were chosen from each mouse and the fluores-
cence intensity of 16 fields per slide was measured and analyzed with VH-H1A5 Analyzer software (KEYENCE, Osaka, Japan). Bars represent means 6 SEM, *p <
0.05 compared to insulin-stimulated FLOX. **p < 0.01 and ***p < 0.0001.L-p85DKO mice have severe defects in glucose
homeostasis
The loss of the insulin stimulated activation of PI3K andAkt in the
liver of L-p85DKO mice and led to significant defects in whole-
body glucose homeostasis. Compared to FLOX controls,
L-p85DKO mice exhibited mild to moderate hyperglycemia in
both the fasted and fed states (Figures 3A and 3C). Furthermore,
these blood glucose levels occurred in the fast of significant hy-
perinsulinemia, with insulin levels increased by 4-fold over con-
trol animals in L-p85DKO mice in both the fasted and fed states
(Figures 3B and 3D). Interestingly, L-aKO mice exhibited im-
proved glucose and insulin levels compared to controls, consis-
tent with previous observations in mice lacking p85a (Fruman
et al., 2000; Terauchi et al., 1999).
In addition, L-p85DKO mice exhibited insulin resistance and
glucose intolerance. Following an intraperitoneal insulin injec-
tion (Figure 3E), mice lacking all hepatic PI3K regulatory sub-
units in liver showed a significant decrease in insulin sensitivity
compared to FLOX controls, as determined by the area under
the curve for fall in glucose levels (Figure 3F). Interestingly,
L-p85DKO mice exhibit whole-body insulin resistance despite
the fact that tissues other than the liver are only homozygousCELL METABOLISM : MAY 2006null for p85b, a defect that has previously been shown to im-
prove insulin sensitivity (Ueki et al., 2002). L-p85DKO also ex-
hibited markedly abnormal glucose tolerance tests consistent
with diabetes (Figure 3G). For the L-p85DKO mice, the area un-
der the curve was almost three times that of control mice
(Figure 3H), whereas L-aKO mice exhibited improved glucose
tolerance compared to FLOX controls (Figures 3G and 3H).
Thus, while a partial deletion of the regulatory subunits may im-
prove glucose homeostasis, loss of all PI3K regulatory subunits
in liver results in diabetes.
The loss of hepatic PI3K/Akt activity leads
to increased gluconeogenesis
One of the hallmarks of diabetes is increased hepatic glucose
output due to failure of insulin to inhibit hepatic gluconeogene-
sis. Since L-p85DKO mice cannot activate Akt and thus phos-
phorylate and inactivate FoxO1, a key regulator of gluconeo-
genic gene expression, we posited that the gluconeogenic
gene cassette should be dysregulated. Indeed, themRNA levels
of critical regulators of gluconeogenesis: PEPCK (Pck1), fruc-
tose 1,6-bisphosphatase (Fbp1), and glucose-6-phosphatase345
A R T I C L EFigure 2. Loss of Hepatic PI3K Activity Leads to Defects in the Akt signaling
A) Liver lysates from insulin-stimulated mice of the indicated genotype were blotted with antibodies against phospho-Akt (Ser473), phospho-FoxO1 (Ser256), phospho-
GSK3b (Ser9). The blots were then stripped and reprobed with antibodies to measure total protein levels.
B)Westerns against phospho-TSC2 (Thr1462) and phospho-S6 proteins (Ser240/244). The blots were then stripped and reprobed with antibodies to measure total protein
levels. The Western blots in this figure are representative of at least three independent experiments.
C) Akt1 and (D) Akt2 kinase assays. (Bars represent 6 SEM, n = 6, *p < 0.05, **p < 0.001, compared to FLOX + insulin).(G6pc) in the L-p85DKO mice were increased 1.5- to 2.2-fold
compared to controls (Figure 4A).
To determine whether this altered pattern of hepatic gene ex-
pression resulted in a functional defect, we subjected
L-p85DKOmice and littermate FLOXand bKOcontrols to a pyru-
vate challenge. In fasting mice, pyruvate is shuttled through the
gluconeogenic pathway in the liver and ultimately converted to
glucose. Thus, by measuring blood glucose after a peritoneal in-
jection of a pyruvate bolus, we are afforded a physiologic read-
out of the relative activity of the enzymes of the gluconeogenic
pathway. Following an injection of pyruvate, L-p85DKO mice
produced significantly more glucose than FLOX and bKO con-
trols (Figure 4B), which indicate that the defects in glucose ho-
meostasis in L-p85DKO mice may stem from the inappropriate
gluconeogenesis in the liver due to a failure of insulin to activate
PI3K and Akt.
L-p85DKO mice exhibit altered lipid metabolism
To better understand how the PI3K pathway affects lipid ho-
meostasis, we measured serum levels of triglycerides, choles-
terol, and free fatty acids (Figures 5A–5C). L-p85DKO mice
showed a 46% reduction in serum triglycerides, a 38% reduc-
tion in total serum cholesterol, and a 35% reduction in free fatty346acids compared to FLOX controls, which were all statistically
significant. The other study groups were not statistically differ-
ent from controls. These physiologic changes correlated with
changes in the molecular machinery that produce hepatic lipids,
as the mRNA expression of SREBP-1c (Srebf1c) and fatty-acid
synthase (Fasn) were significantly decreased in L-p85DKOmice
(Figure 5D). Interestingly, L-aKObH mice also showed a statisti-
cally significant decrease in Srebf1c expression, whereas the
other genotypes did not exhibit changes in either of these regu-
lators of lipid metabolism. Since Akt activity was not diminished
in these mice, we wondered if other PIP3-dependent kinases,
such as PKCl/z, could be responsible for regulating the expres-
sion of Srebf1c.
Given the prominent role that PKCl/z may play in regulating
mRNA levels of SREBP-1c (Matsumoto et al., 2003), we mea-
sured PKCl/z kinase activity and found that insulin normally
activated PKCl/z in FLOX, bKO, and L-aKO mice (Figure 5E),
whereas both L-aKObHmice and L-p85DKOmice exhibited sig-
nificant defects in PKCl/z activation, where insulin only margin-
ally activated the kinase above basal levels. The magnitude of
PKCl/z activity paralleled the levels of Srebf1c expression, as
has been noted in other studies (Matsumoto et al., 2003; Stand-
aert et al., 2004).CELL METABOLISM : MAY 2006
PI3K-mediated regulation of hepatic metabolismFigure 3. L-p85DKO exhibit significant defects in
glucose homeostasis
Blood glucose and serum insulin levels in the fasted
(A and B) and random fed (C and D) states. Glucose
and insulin levels are plotted as themean6 SEM (n =
6–12 mice per genotype).
E) Insulin tolerance tests (1 U/kg, intraperitoneally).
Results represent blood glucose concentration as
a percentage of starting value at zero time and are
expressed as means 6 SEM (n = 6–8).
F) Results from (E) expressed as area under ITT
curves (see Experimental Procedures).
G) Glucose tolerance tests (2 g/kg, intraperitoneally)
were performed on mice following a 16 hr fast. Blood
samples were collected and glucose measured at
the times indicated.
H) Results from (G) expressed as area under GTT
curves (see Experimental Procedures). Bars equal 6
SEM, *p < 0.05 compared to FLOX.
Open circles (B), bold line—FLOX; open triangles
(6), dashed line—bKO; closed squares (-), bold
line—L-aKO; open squares (,), dashed line—L-
aKObH; closed circles (), bold line—L-p85DKO.The Activation of PKCl/z, but not Akt, is sufficient
to upregulate hepatic SREBP-1c expression
To clarify whether Akt or PKCl/z plays the dominant role in ac-
tivating SREBP-1c, we reconstituted the livers of L-p85DKO
mice with constitutively active forms of Akt (Myr-Akt) or PKCl
(CA-PKCl) using adenovirus-mediated gene transfer, which
specifically targets the liver (Taniguchi et al., 2005). We rea-
soned that the hepatic expression of constitutively active con-
structs in fasted L-p85DKO mice would greatly reduce the pos-
sibility of surreptitious activation of SREBP-1c by mechanisms
unrelated to Akt or PKCl/z. Littermate FLOX and bKO mice
were also injected with these adenoviruses as genetic controls.
Wefirst verified thatweachieved theproperexpressionof these
constructs in the liverbyWesternblot andkinaseassay.Bothcon-
stitutively active gene products are distinguishable by Western
since the myr-Akt construct contains a C-terminal myc-tag
(Sakoda et al., 2003) while the constitutively active PKCl con-
struct lacks its autoinhibitory pseudosubstrate domain and isCELL METABOLISM : MAY 2006thus truncated by approximately 15 kDa compared to wt PKCl
(Kotani et al., 1998). Immunoblots forAkt andPKCldemonstrated
that the tail vein injections successfully expressed the constitu-
tively active constructs in the liver (Figure 6A). These constructs
also increased the relative activity of each kinase,where the injec-
tion of Myr-Akt adenovirus caused a 6.0- to 8.5-fold increase in
total Akt activity (Figure 6B), and the CA-PKCl virus resulted in
a 3.0- to 4.0-fold increase in PKCl activity compared to fasted
FLOX mice treated with control LacZ adenovirus (Figure 6C).
As expected, introduction of the Myr-Akt adenovirus to either
the FLOX, bKO, or L-p85DKO mice resulted in the profound in-
hibition of both Pck1 and G6pc expression in liver in all geno-
types, compared to the fasted FLOX control treated with LacZ
(Figures 6D and 6E). Interestingly, expression of CA-PKCl
also inhibited the expression of Pck1 by 65%–75% and G6Pc
by 50%–60% in all genotypes (Figures 6D and 6E), though
only the Pck1 expression was significantly different from fasted
FLOX controls treated with LacZ.347
A R T I C L EFigure 4. Defects in glucose homeostasis are linked to increased gluconeogenesis
A)Quantitative RT-PCR analysis of mRNA levels of phosphoenolpyruvate carboxykinase (Pck1), glucose-6-phosphatase (G6Pc), and fructose-1,6-bisphosphatase (Fbp1)
in mice of the indicated genotypes.
B) Pyruvate challenge of L-p85DKO and control FLOX and bKO mice. Following a 16 hr fast, mice were injected intraperitoneally with a 2 g/kg bolus of pyruvate in normal
saline. Blood glucose was thenmeasured at the indicated time points. Open circles (B), bold dashed line—FLOX; open triangles (6), dashed line—bKO; closed circles (),
bold line—L-p85DKO. (Bars equal 6 SEM, *p < 0.05, **p < 0.01 compared to FLOX.)The expression of SREBP-1c mRNA, on the other hand, was
increased by 5- to 6-fold in all genotypes by CA-PKCl, demon-
strating that atypical PKCactivity is sufficient to increaseSrebf1c348levels (Figure 6F). Constitutive Akt activity, on the other hand,
had no discernable effect on fasting Srebf1c expression as
compared to mice treated with LacZ. These data demonstrateFigure 5. L-p85DKO mice are hypolipidemic
A) Serum triglycerides (B) cholesterol and (C) free fatty acids in mice of the indicated genotype (n = 6–8 6 SEM, *p < 0.05).
D) Quantitative RT-PCR analysis of mRNA levels of SREBP-1c (Srebf1c) and fatty-acid synthase (Fasn) in mice of the indicated genotypes (n = 6–86 SEM *p < 0.05, **p <
0.01, compared to FLOX).
E) Kinase activity of atypical protein kinase C (PKC z/l) expressed as cpm. (n = 3–4 6 SEM, **p < 0.01, compared to FLOX + insulin.)CELL METABOLISM : MAY 2006
PI3K-mediated regulation of hepatic metabolismFigure 6. PKCl/z activity is sufficient to increase levels of hepatic Srebf1c expression
A) Western blots against myc-tagged myristoylated Akt and total PKCl/z in liver lysates of mice injected with the indicated adenovirus. The CA-PKCl construct runs
approximately 15 kDa smaller than wt PKCl because it lacks the autoinhibitory pseudosubstrate domain (w115 amino acids).
B) Akt kinase activity and (C) PKCl/z kinase activity from liver lysates of fastedmice of indicated genotype and injected with the indicated adenovirus. Quantitative RT-PCR
analysis of (D) Pck1, (E)G6Pc, and (F) Srebf1c of fasted mice of indicated genotype, injected with the indicated adenovirus. The error bars represent6 SEM (n = 6–8, *p <
0.05, **p < 0.001, compared to FLOX + LacZ).that the activity of PKCl/z mediated via the PI3K pathway, and
not the activity of Akt, defines the level of insulin effect on
SREBP-1c expression.
Loss of hepatic PI3K causes altered liver growth
and compensatory changes in body fat
The PI3K/Akt axis mediates cell growth and protein synthesis
through its activation of the mTOR in a pathway involving
TSC2 and p70S6 kinase. Since L-p85DKO mice exhibit signifi-
cant defects in TSC2 phosphorylation and mTOR activation
(Figure 2), we posited that L-p85DKO mice may also have de-
fects in hepatocyte growth. Indeed, the livers of L-p85DKO
mice werew40% smaller than the livers of wt mice (Figure 7A).
Histological examination of these livers revealed a significant in-
crease in the number of pyknotic cells and scattered lympho-
cytic infiltrates in four of the five livers analyzed (Figure 7B).
The livers of other genotypeswere largely normal, though a small
percentage of mice lacking Pik3r1 in liver exhibited a mild de-
gree of hepatic necrosis, as reported earlier (Fruman et al.,
2000). Livers lacking all PI3K regulatory subunits were also re-
markable for the presence of megahepatocytes that ranged
between 40 and 60 microns in diameter as compared to an
average normal hepatocyte size of between 15 and 24 microns
(Figure 7B). These megahepatocytes were notable for large nu-
clei with cytoplasmic inclusions, indicating that these cells were
likely polyploid with highly abnormal cellular function. WhetherCELL METABOLISM : MAY 2006these megahepatocytes are formed from abnormal hepatocyte
growth or are a product of cell fusion mediated by inflammation
is unknown.
This abnormal liver histology correlated with increased levels
of the hepatic enzymes, aspartate aminotransferase (AST) and
alanine aminotransferase (ALT), and decreased levels of albu-
min in the serum of L-p85DKO (Table S1). In addition, total bili-
rubin levels were significantly elevated with no detectable level
of direct bilirubin indicating a rise in indirect, or unconjugated,
bilirubin. The presence of decreased albumin, increased AST,
ALT, indirect bilirubin, and pyknotic cells in the histological sam-
ples in L-p85DKO mice is consistent with some destruction of
hepatocytes and altered hepatic function (Figure 7B). The other
genotypes did not display a significant increase in serum levels
of AST, ALT, or bilirubin; a significant decrease in albumin; or
any histological changes.
We were somewhat surprised to find that the smaller livers in
L-p85DKO mice did not translate to lower overall body weights,
as there were no significant weight differences between geno-
types, except for a slight increase in total body weight in bKO
mice (Figure 7C). Weweighed other tissues in the body to deter-
mine if the weight of any one particular tissue could account for
this difference, of if the normalized weight was due to a general
enlargement of other tissues to maintain body weight. Surpris-
ingly, the epididymal fat pads of the L-p85DKO mice were
2-fold heavier than the epididymal fat pads of control FLOX349
A R T I C L EFigure 7. Lack of hepatic PI3K activity results in altered liver morphology and adipose tissue size and function
A) Liver weights from mice of the indicated genotype, normalized to total body weight.
B)Histology of L-p85DKO livers compared to control livers. Note the presence of megahepatocytes (bottom right panel) that are scattered in clusters throughout the field in
L-p85DKO livers (indicated by arrows in upper right panel).
C) Total body weight and (D) epididymal fat pad weights of mice of the indicated genotypes.
E) Serum leptin and (F) serum adiponectin of various knockout mice. The bars represent 6 SEM (n = 6–8, *p < 0.05, **p < 0.01, compared to FLOX).mice, while the epididymal fat pads of bKO mice were almost
3-fold larger than controls, and the epididymal fat pads of
L-aKObHmicewerew1.8-fold greater than controls (Figure 7D).
This increase in adipose mass was accompanied by an 8-fold
increase in serum leptin levels (Figure 7E) and a 2.5-fold increase
in adiponectin levels (Figure 5F) in L-p85DKOmice. Therewasno
change in these circulating adipokines in other genotypes.
Discussion
Insulin is a powerful anabolic hormone whose function in liver is
to suppress gluconeogenesis and activate lipogenesis during
times of nutrient excess. Thus, the loss of ablation of insulin ac-
tion in liver would be predicted to cause unfettered gluconeo-
genesis, decreased lipogenesis, and diabetes, which is the phe-
notype observed in L-p85DKOmice. Interestingly, themetabolic
defects of L-p85DKO mice are similar to the severe glucose in-
tolerance and hypolipidemia observed in liver insulin receptor
knockout (LIRKO) mice, further demonstrating that PI3K medi-
ates most of insulin’s regulatory functions in the liver (Michael
et al., 2000).
While the prominence of the PI3K pathway in hepatic insulin
action has been posited for some time, the molecular mediators
of insulin’s effect on glucose and lipid metabolism have only re-350cently been explored. Our data agree with several other reports
that hepatic glucose metabolism is regulated strongly by PI3K/
Akt (Puigserver et al., 2003; Zhang et al., 2002). The loss of PI3K/
Akt in the L-p85DKOmice impairs Akt activation by 90% and re-
sults in the increased expression of the gluconeogenic genes
Pck1,G6Pc, and Fbp1. Conversely, the introduction of a consti-
tutively active Akt into the livers of L-p85DKO or control animals
causes >90% reduction of fasting levels of Pck1 and G6pc. We
also found that this regulation of gluconeogenesis was not de-
pendent on differences in activity between Akt1 or Akt2. While
we cannot rule out the possibility that the various Akt isoforms
may interact with different downstreammediators or have differ-
ent subcellular localization, our data suggest that it is unlikely
that the differences in the biology of the Akt isoforms comes
from the upstream activation by PI3K since both Akt1 and
Akt2 maintained full activation until PIP3 was fully depleted in
the L-p85DKO mice.
While Akt has been clearly demonstrated to mediate insulin’s
suppression of gluconeogenesis, the role of Akt in the regulation
of insulin-mediated lipogenesis is more controversial. Our data
indicate that Akt may play only a minor role in activating lipogen-
esis, as the administration of a constitutively active Akt adenovi-
rus to L-p85DKO or control animals failed to increase Srebpf1c
levels in fasted animals. On the other hand, we demonstratedCELL METABOLISM : MAY 2006
PI3K-mediated regulation of hepatic metabolismthat atypical PKC activity alone is sufficient to increase the ex-
pression of Srebf1c since the expression of a constitutively
active PKCl/z construct specifically in the hepatocytes of
L-p85DKO or control animals upregulated Srebf1c expression
5- to6-foldover fastedcontrol animals injectedwith LacZadeno-
virus. The converse relationmay also be true since L-aKObHand
L-p85DKO both exhibited significant impairments in both PKCl/
z activity and Srebf1c expression. These data complement and
significantly expand upon previously published knockout stud-
ies that demonstrate that atypical PKC activity is necessary for
insulin-induced Srebf1c expression (Matsumoto et al., 2003).
Together, these data suggest a primary role of PI3K/atypical
PKCs in regulating Srebf1c levels in response to insulin.
The precisemechanisms by which PKCl/z increases the tran-
scription of SREBP-1c are not well understood. The liver X re-
ceptor (LXR) pathway has been postulated to play a primary
role in the insulin-mediated induction of Srebf1cmessage levels
(Chen et al., 2004). Whether the atypical PKCs interact with any
factor related to the LXR pathway is not known, however, since
the in vivo substrates of the atypical PKCs have not yet been de-
fined. Indeed, the elucidation of the targets of PKCl/z will be
essential to understanding the molecular basis of aPKC-depen-
dent regulation of SREBP-1c transciption.
Interestingly, the divergence in insulin’s regulation of hepatic
glucose and lipid was detected due to a difference in the activa-
tion of Akt and aPKC in the various p85 hypomorphs. Our data
suggest that Akt may be more sensitive to insulin/PIP3 than
PKCl/z since Akt could be fully activated in the aKObHet mice
despite the fact the levels of PIP3 were reduced by w50%
(see Figure 1D), while PKCl/z activity in these mice was mark-
edly diminished (see Figure 5E). The molecular basis for this dif-
ferential activation is not known but could be due to differences
in their PIP3 binding or some other aspect of aPKC activation,
such as autophosphorylation or inhibition by its pseudosub-
strate domain (Farese et al., 2005).
Phosphoinositide 3-kinase controls several other important
aspects of hepatocyte function in addition to metabolism. In
particular, the PI3K/Akt/mTOR pathway was severely impaired
in L-p85DKO mice as manifested by decreased TSC2 and S6
phosphorylation. These defects in translational control by PI3K
lead to a 40% decrease in liver size and a 60% decrease in al-
bumin synthesis. In addition, L-p85DKO mice exhibited abnor-
mal histology and elevated levels of serum AST, ALT, and
indirect (unconjugated) bilirubin (see Table S1). Despite these in-
dications of liver damage, L-p85DKOmice were able to respond
in an exaggerated way to a pyruvate challenge (Figure 4B), indi-
cating that the hyperglycemia and probably the other defects in
glucose homeostasis in L-p85DKO mice were a result of the in-
creased expression of functional gluconeogenic enzymes
(Figure 4A), and not some aspect of hepatic insufficiency.
The loss of hepatic PI3K activity also led to changes in adipose
tissue physiology. The epididymal fat pads in the L-p85DKO
were almost 2-fold larger than controls, which is most likely
due to the moderate and persistent hyperinsulinemia that leads
to a substrate shift to adipocytes. This phenomenon has been
observed in other models of insulin resistance and diabetes
such as liver insulin receptor knockout (LIRKO) mice (Michael
et al., 2000) and muscle insulin receptor knockout (MIRKO)
mice (Bruning et al., 1998). In addition, L-p85DKOmice exhibited
significant increases in the twomajor adipokines, leptin and adi-
ponectin. These increases are probably not a cell-autonomousCELL METABOLISM : MAY 2006effect of adipose tissue since the elevated leptin and adiponectin
are increased only in the L-p85DKO mice, despite the bKO and
L-aKObH mice having epididymal fat pads nearly equal in size
or larger than those in the L-p85DKO mice. Interestingly, LIRKO
mice also display striking increases in serum leptin levels (>60-
fold over controls) as a compensatory response to a 450-fold in-
crease in soluble leptin receptor expression by the liver (Cohen
and C.R.K., unpublished data). The relationship between insu-
lin-stimulated PI3K activity and leptin receptor expression ob-
served in LIRKO may also explain the elevated leptin levels in
L-p85DKO mice, as L-p85DKO mice have a 12-fold increase in
soluble leptin receptor expression (data not shown) to match
the 5-fold increase in serum leptin (Figure 7E).
In summary, deletion of all major regulatory subunits of PI3K in
liver results in a marked reduction in insulin-stimulated PI3K ac-
tivity and PIP3 accumulation in liver and significant defects in
glucose and lipid homeostasis, as well as in hepatic size and
function. Thus, the PI3K pathway is essential for metabolic ho-
meostasis and cell growth, and PI3K activity is responsible for
nearly all of insulin’s actions in the liver in vivo. Moreover, the
specific regulation of glucose and lipid homeostasis by insulin
diverges after PI3K activation, where it appears that Akt selec-
tively and potently regulates gluconeogenesis whereas PKCl/z
increases Srebf1c expression. The differential actions of the
PI3K-dependent kinases, Akt and PKCl/z, may represent the
primary mechanisms by which insulin regulates different as-
pects of hepatic metabolism. Understanding thesemechanisms
not only helps to clarify the important regulators in hepatic func-
tion but may also provide more specific ways to improve many
complications of diabetes and the metabolic syndrome.
Experimental procedures
Animals and breeding strategy
All animals were housed on a 12 hr light-dark cycle and fed a standard rodent
chow. All protocols for animal use and euthanasia were approved by the
Animal Care Use Committee of the Joslin Diabetes Center and Harvard Med-
ical School in accordance with National Institutes of Health guidelines. All
mice in this study were on a 129Sv-C57BL/6-FVB mixed genetic back-
ground. The breeding strategy in this study involved the crossing of homozy-
gous floxed Pik3r1 mice with Pik3r2 homozygous null mice to create mice
homozygous for both the Pik3r1 floxed allele and the Pik3r2 null allele
(Pik3r1fl/fl, Pik3r22/2). These mice were then bred with L-aKObH
(L-Pik3r12/2, Pik3r2+/2) mice, also on a mixed background, which contain
the albumin-Cre transgene, to produce the five groups used in this study.
Quantitative Reverse Transcription PCR analysis
Total RNAwas isolated frommouse tissues using anRNeasy kit (QIAGEN, Va-
lencia, California). cDNAwas prepared from 1 mg of RNA using the Advantage
RT-PCR kit (BD Biosciences, Palo Alto, California) with random hexamer
primers, according tomanufacturer’s instructions. The resulting cDNAwasdi-
luted 10-fold, and a 5 ml aliquotwas used in a 20ml PCR reaction (SYBRGreen,
PE Biosystems) containing primers at a concentration of 300 nM each. PCR
reactions were run in triplicate and quantitated in the ABI Prism 7700 Se-
quence Detection System. Ct values were normalized to TATA box binding
protein (TBP) expression, and results were expressed as a fold change of
mRNA compared to the indicated control mice. Primers for Pck1, G6Pc,
Fbp1, Srebf1c, and Fasn were described previously (Taniguchi et al., 2005).
Primers for p85bwere designed across exon 1 and exon 2 since exon 1 is de-
leted in Pik3r2 knockout mice. The forward primer for p85b is CCCTTGGATG
GATCTTCTGA and the reverse primer is TCCACCAGCTTCACCAGAAT.
Metabolic studies
For glucose tolerance testing (GTT), blood samples were obtained at 0, 15,
30, 60, and 120 min after intraperitoneal injection of 2 g/kg dextrose. Insulin351
A R T I C L Etolerance tests were performed by injecting 1 U/kg insulin (Novolin, Novo
Nordisk, Denmark) intraperitoneally, followed by blood collection at 0, 15,
30, and 60 min. The pyruvate challenge was performed by injected 2 g/kg
of pyruvate (Sigma) intraperitoneally, with blood glucose measured at 0,
15, 30, and 60 min time points. Blood glucose values were determined using
a One Touch II glucosemonitor (Lifescan Inc., Milipitas, California). Serum in-
sulin and leptin levels weremeasured by ELISA usingmouse insulin as a stan-
dard (Crystal Chem Inc., Chicago, Illinois). Serum adiponectin levels were
analyzed from diluted mouse serum (1/1000) and analyzed by an ELISA kit
(Linco). Nonesterified free fatty-acid levels were measured from random
fed mice using a kit from Wako Diagnostics. The serum levels of the liver en-
zymes, bilirubin, total protein albumin, and triglycerides were measured by
Anilytics (Gaithersburg, Maryland).
In vivo insulin signaling
Following an overnight fast, mice were anesthetized with 2,2,2-tribromoetha-
nol in PBS (Avertin), and injected with 5 U of regular human insulin (Novolin,
Novo Nordisk, Denmark) via the inferior vena cava. Five minutes after the in-
sulin bolus, tissues were removed and frozen in liquid nitrogen. Immunopre-
cipitation and immunoblot analysis of insulin signaling molecules were per-
formed using tissue homogenates prepared in a tissue homogenization
buffer that contained 25 mM Tris-HCl (pH 7.4), 10 mM Na3VO4, 100 mM
NaF, 50 mM Na4P2O7, 10 mM EGTA, 10 mM EDTA, 2 mM phenylmethylsul-
fonyl fluoride, 1% Nonidet-P40 supplemented with the Complete protease
inhibitor cocktail (Roche). All protein expression data were quantified by den-
sitometry using NIH Image.
Antibodies
Rabbit polyclonal anti-IRS-1 antibody (IRS-1), anti-IRS-2 antibody (IRS-2),
anti-IR antibody (IR), and pan-p85a antibody were generated as described
previously (Ueki et al., 2002). Rabbit polyclonal anti-Akt, anti-phospho Akt
(S473), anti-phospho FoxO1, anti-phospho GSK3b (Ser9), anti-FoxO1, anti-
GSK3, anti-phosphoTSC2 (Thr1462), anti-TSC2, anti-phospho S6 (Ser240/
244), and anti-S6 antibodies were purchased from Cell Signaling Technology
(Beverly, Massachusetts). Myc-tag and isoform-specific Akt antibodies were
purchased from Upstate Biotechnology (Lake Placid, New York). A poly-
clonal antibody for Westerns and immunoprecipitation against PKCl/z was
purchased from Santa Cruz Biotechnology.
PIP3 quantitation
Phosphatidylinositol(3,4,5)-triphosphate (PIP3) levels were measured by
a monoclonal antibody (IgM, Echelon Biosciences) as described previously
(Kitamura et al., 2004), with a few modifications. Following insulin or saline
treatment, mice were fixed by cardiac perfusion of 10% buffered formalin.
The livers were then dehydrated in 30% sucrose overnight, then frozen in
OCT compound (Sakura) for sectioning. For quantification of the immunoflu-
orescence, four representative slides were chosen from each mouse and the
fluorescence intensity of 16 fields per slide was measured and analyzed with
VH-H1A5 analyzer software (KEYENCE, Osaka, Japan).
In vitro kinase assays
Livers were extracted into tissue homogenization buffer and subjected to im-
munoprecipitation with IRS-1, IRS-2, or pTyr for PI3K assays as described
previously (Taniguchi et al., 2005). Isoform-specific Akt antibodies were
used to immunoprecipitate Akt1 or Akt2 from liver lysates then were sub-
jected to Crosstide assay as described previously (Sakamoto et al., 2002).
Reactions for atypical PKC activity were performed as reported previously
(Sajan et al., 2004).
Statistics
Data are presented as 6 SEM. Student’s t test was used for statistical anal-
ysis between two groups, while statistical significance between multiple
treatment groups was determined by analysis of variance (ANOVA) and
Tukey’s t test. The trapezoid method was used to calculate area under the
curve for ITT and GTT curves (Tran et al., 1996).
Supplemental data
Supplemental data include one table and can be found with the article online
at http://www.cellmetabolism.org/cgi/content/full/3/5/343/DC1/.352Acknowledgments
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